Recent Updates
Recently added Catalysts
ARTV Positive Sentiment

Beyond Biotech Podcast: Natural Killer Cells

Thursday, November 2, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Artiva Biotherapeutics' CEO, Fred Aslan, discussed key advancements in NK cell therapies on the Beyond Biotech Podcast. The company showcased promising results from two cancer clinical trials and highlighted receiving FDA clearance for an IND for lupus. This marks a significant development in allogeneic NK cell therapies for autoimmune diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Demonstrated efficacy and safety in cancer trials.
  • FDA clearance for IND for lupus is a significant milestone.
  • AlloNK offers a novel approach to treating autoimmune diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+215%
120-day peak, hindsight
Typical move
13.1%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK Cells
Phase 2 · Refractory Rheumatoid Arthritis (RA)

Full Press Release Details

Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. was featured on the Beyond Biotech Podcast hosted by Labiotech.eu to discuss recent milestones including:
• Demonstrating the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials, and
• Receiving FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.
AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the outpatient setting.
Listen to the podcast here .

Frequently Asked Questions

What did Artiva Biotherapeutics discuss on the podcast?

The podcast featured Artiva's CEO discussing NK cell therapy advancements and FDA clearance.

What is AlloNK?

AlloNK is a non-genetically modified NK cell therapy candidate derived from cord blood.

What milestone did Artiva achieve regarding lupus?

Artiva received FDA clearance for an IND for lupus, a first for allogeneic NK therapies.

What are the applications of AlloNK?

AlloNK is intended for use with monoclonal antibodies in outpatient settings.

ShareAdd on Google
Tags: ARTV Viatris Investor Conferences Healthcare Artiva Biotherapeutics NK cells FDA clearance lupus cancer trials
Last updated: Nov 2, 2023

Biotech snapshot

Cash runway
$349M liquidity · $7M/mo burn
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK CellsPhase 2
Refractory Rheumatoid Arthritis (RA) →

Catalyst track record

+215%
best trade around ARTV's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ARTV.

See every catalyst's timing & PoA →